How Do MASP-2 Inhibitors Work?

Mannose-binding protein-associated serine protease 2 (MASP-2) inhibitors include a novel drug narsoplimab, a human monoclonal antibody, which is undergoing clinical trials to be used for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab inhibits the enzyme MASP-2, also known as mannan-binding lectin serine protease 2, of the lectin pathway.

The complement system is a part of the immune system that enhances the ability of antibodies and phagocytes to clear microbes and damaged cells, attack pathogens, and promote inflammation. The complement system has several pathways, wherein the lectin pathway is the principal one activated by tissue damage and microbial infection.

The novel drug narsoplimab prevents complement-mediated inflammation and endothelial damage; it does not alter the functions of other pathways of the immune system.

Narsoplimab is not approved by the US Food and Drug Administration (FDA), but it is granted priority review for a Biologics License Application process for the treatment of HSCT-TMA.

MASP-2 inhibitor is undergoing clinical trials to be used for the treatment of:

• HSCT-TMA
• IgG nephropathy

Side effects associated with MASP-2 inhibitor include:

• Headache
• Upper respiratory tract infections
• Fatigue
• Diarrhea
• Nausea
• Fatigue
• Hypokalemia
• Neutropenia
• Vomiting
• Infection due to neutropenia
• Kidney failure

The information contained herein is not intended to cover all possible side effects, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Check with your doctor or pharmacist to make sure these drugs do not cause any harm when you take them along with other medicines. Never stop taking your medication and never change your dose or frequency without consulting your doctor.

Generic and brand names of MASP-2 inhibitor includes:

• Narsoplimab (Pending FDA Approval)